by Öner Tulum, William Lazonick, and Ken Jacobson This is the second installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
Author: Oner Tulum
#8. Scaling of COVID vaccine manufacturing: It’s all about the lipids
by Öner Tulum, William Lazonick, and Ken Jacobson This is the first installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#7. Scaling of COVID vaccine manufacturing: What are the problems that can occur in the early stages?
by Öner Tulum, William Lazonick, and Ken Jacobson In March 2020, as a number of developers announced COVID-vaccine candidates that would begin clinical trials, vaccine manufacturers around the…
#6. Scaling of COVID vaccine manufacturing: Does the CEO understand the extraordinary complexities involved?
by Öner Tulum, William Lazonick, Ken Jacobson, and Ellen Chappelka During an interview on December 18, 2020, Moderna CEO Stéphane Bancel revealed his “Never Again Plan,” which…
#5. Scaling of COVID vaccine manufacturing: What manufacturing activities are involved and why are they so difficult?
by Öner Tulum, William Lazonick, and Ken Jacobson In March and April 2021, Americans received as many as four million doses a day of COVID-19 vaccines, far…
#4. Who are the CDMOs? For whom is their capacity being deployed to produce COVID vaccines?
by Öner Tulum, William Lazonick, and Ken Jacobson In responding to the COVID-19 pandemic, the global pharmaceutical industry has…
Stock Buybacks Stand in the Way of Biden’s Infrastructure Plan
Hedge fund managers are pushing American firms to play Wall Street games instead of investing in technologies of the future. China doesn’t have that problem.
#3. Where do those COVID vaccines come from?
by Öner Tulum, William Lazonick, and Ken Jacobson The success of the worldwide COVID-vaccine rollout depends on decisions regarding the utilization of available production capacity made both independently…
#1. Is there enough production capacity available for the vaccine supply to meet urgent demand in 2021?
by Öner Tulum, William Lazonick, and Ken Jacobson As COVID-19 vaccines receive regulatory approval, the world has a powerful weapon to fight the coronavirus. But at what pace…
INET-AIR COVID VACCINE PROJECT
Mass-Producing COVID-19 Vaccines: Capacity, Scale, and Control In collaboration with the Institute for New Economics Thinking (INET), the AIR research team has embarked on a new research project (INET-AIR COVID VACCINE PROJECT) to study and report on the rollout of…